Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood

J P Ernst1, H Doose, W K Baier

  • 1Department of Neuropediatrics, University of Kiel, West Germany.

Brain & Development
|January 1, 1988
PubMed

Insights

Potassium bromide therapy can be effective for children with drug-resistant epilepsy, particularly those with generalized tonic-clonic seizures. While not a cure, it offers significant seizure reduction for many patients.

Area of Science:

  • Neurology
  • Pediatric Epilepsy
  • Pharmacology

Background:

  • Epilepsy in children often presents treatment challenges.
  • Drug-resistant epilepsy requires exploration of alternative therapeutic options.

Purpose of the Study:

  • To evaluate the efficacy and safety of potassium bromide as an add-on therapy for children with refractory epilepsy.
  • To determine optimal dosage and identify patient subgroups most likely to benefit.

Main Methods:

  • A cohort of 36 children with epilepsy resistant to conventional treatments received potassium bromide.
  • Seizure frequency and type were monitored before and during bromide treatment.
  • Side effects and dosage were systematically recorded.

Main Results:

  • Six of 19 children with generalized tonic-clonic seizures became seizure-free.
  • Nine patients achieved over 50% reduction in seizure frequency.
  • No significant response was observed in tonic or focal seizures; some minor seizures worsened.
  • Common side effects included acne, appetite/weight loss, and fatigue, all manageable.

Conclusions:

  • Potassium bromide is a viable treatment option for pediatric epilepsy, especially for generalized tonic-clonic seizures unresponsive to other therapies.
  • An effective daily dose ranges from 50 to 80 mg/kg.
  • Ideal candidates are children with early-onset epilepsy and generalized tonic-clonic seizures, with careful monitoring for side effects.

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...